Mologen To Pursue Combinations Only After Lefitolimod’s Solo IMPALA Failure

 
• By Sten Stovall

Mologen’s CEO tells Scrip the German biotech will only pursue combination studies in future after its lead candidate lefitolimod failed as a monotherapy in a pivotal trial treating metastatic colorectal cancer patients.

Dart
Mologen ends monotherapy approach for lefitolimod after Phase III failure • Source: Shutterstock

More from Clinical Trials

More from R&D